Efficacy of topical sildenafil formulations in enhancing wound healing outcomes: a narrative review
Abstract
Sildenafil, a major phosphodiesterase type 5 (PDE5) inhibitor, is particularly known for treating erectile dysfunction. It has been suggested as a promising therapeutic medication for accelerating wound healing. This study aimed to summarize the efficacy of different formulations and dosages of sildenafil in enhancing wound healing, focusing on its formulations, dosages, and mechanisms of action. The study used relevant keywords to review studies involving animal models and human patients. No time limitation was considered in the current study. The outcomes measured included re-epithelization, vascularization, collagen formation, and overall healing efficacy. Topical sildenafil formulations indicated significant improvements in wound closure, vascularization, and collagen regeneration in skin wounds. A combination of platelet-rich plasma (PRP) and sildenafil increased skin wound healing. Different concentrations (topical 2% and 5% formulation, and 13 mg/kg orally) were useful, with specific dosages showing significant improvements in healing biomarkers. The underlying mechanisms of sildenafil for accelerating wound healing are increasing nitric oxide (NO) levels and collagen synthesis. Moreover, sildenafil triggers angiogenesis, and fibroblast migration and contributes to skin tissue repair and regeneration. Topical sildenafil can be a promising drug for increasing wound healing, with different formulations and dosages illustrating efficacy in improving healing outcomes.…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.